D Heather Watts1, Elizabeth R Brown, Yvonne Maldonado, Casey Herron, Tsungai Chipato, Leanne Reddy, Dhayendre Moodley, Clemensia Nakabiito, Karim Manji, Wafaie Fawzi, Kathleen George, Paul Richardson, Sheryl Zwerski, Hoosen Coovadia, Maryglenn Fowler. 1. *Maternal and Pediatric Infectious Disease Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, Bethesda, MD; †Fred Hutchinson Cancer Research Center, Seattle, WA; ‡Department of Pediatrics, Stanford University School of Medicine, Palo Alto, CA; §University of Zimbabwe College of Medicine, Harare, Zimbabwe; ‖Centre for the AIDS Programme of Research in South Africa (CAPRISA), Nelson R Mandela School of Medicine, University of KwaZulu Natal, Durban, South Africa; ¶Makerere University-Johns Hopkins University Research Collaboration, Kampala, Uganda; #Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania; **Harvard School of Public Health, Boston, MA; ††Family Health International, Research Triangle Park, Chapel Hill, NC; ‡‡Johns Hopkins Medical Institutes, Baltimore, MD; §§National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD; ‖‖Maternal Adolescent and Child Health, University of the Witwatersrand, Johannesburg, South Africa, and ¶¶Statistical Center for HIV/AIDS Research and Prevention (SCHARP), Seattle, WA.
Abstract
BACKGROUND: Starting lifelong antiretroviral therapy (ART) in HIV-infected pregnant women may decrease HIV progression and transmission, but adherence after delivery may be difficult, especially for asymptomatic women. We evaluated disease progression among HIV-infected women not on ART with CD4⁺ lymphocyte counts above 200 cells per microliter at delivery. METHODS: We analyzed risk of death, progression to AIDS (stage IV or CD4 < 200 cells per microliter), or to CD4⁺ count <350 1 year after delivery among postpartum women enrolled to a prevention of breastfeeding transmission trial using the Kaplan-Meier method. In the primary analysis, women were censored if ART was initiated. RESULTS: Among 1285 women who were not WHO stage IV or less at 6 weeks postpartum, 49 (4.3%) progressed to stage IV/CD4 <200 cells per microliter or death by 1 year. Progression to CD4 <200 cells per microliter or death occurred among 16 (4.3%) of 441 women with CD4 count of 350-549 cells per microliter and 10 (1.6%) of 713 with CD4 counts >550 cells per microliter at delivery. CD4 <350 cells per microliter by 12 months postpartum occurred among 116 (37.0%) of 350 women with CD4 count 400-549 cells per microliter and 48 (7.4%) of 713 with CD4 count >550 cells per microliter at delivery. CONCLUSIONS: Progression to AIDS or CD4 count <350 cells per microliter is uncommon through 1 year postpartum for women with CD4 counts over 550 cells per microliter at delivery, but occurred in over one third of those with CD4 counts under 550 cells per microliter. ART should be continued after delivery or breastfeeding among women with CD4 counts <550 cells per microliter if follow-up and antiretroviral adherence can be maintained.
BACKGROUND: Starting lifelong antiretroviral therapy (ART) in HIV-infected pregnant women may decrease HIV progression and transmission, but adherence after delivery may be difficult, especially for asymptomatic women. We evaluated disease progression among HIV-infectedwomen not on ART with CD4⁺ lymphocyte counts above 200 cells per microliter at delivery. METHODS: We analyzed risk of death, progression to AIDS (stage IV or CD4 < 200 cells per microliter), or to CD4⁺ count <350 1 year after delivery among postpartum women enrolled to a prevention of breastfeeding transmission trial using the Kaplan-Meier method. In the primary analysis, women were censored if ART was initiated. RESULTS: Among 1285 women who were not WHO stage IV or less at 6 weeks postpartum, 49 (4.3%) progressed to stage IV/CD4 <200 cells per microliter or death by 1 year. Progression to CD4 <200 cells per microliter or death occurred among 16 (4.3%) of 441 women with CD4 count of 350-549 cells per microliter and 10 (1.6%) of 713 with CD4 counts >550 cells per microliter at delivery. CD4 <350 cells per microliter by 12 months postpartum occurred among 116 (37.0%) of 350 women with CD4 count 400-549 cells per microliter and 48 (7.4%) of 713 with CD4 count >550 cells per microliter at delivery. CONCLUSIONS: Progression to AIDS or CD4 count <350 cells per microliter is uncommon through 1 year postpartum for women with CD4 counts over 550 cells per microliter at delivery, but occurred in over one third of those with CD4 counts under 550 cells per microliter. ART should be continued after delivery or breastfeeding among women with CD4 counts <550 cells per microliter if follow-up and antiretroviral adherence can be maintained.
Authors: Louise Kuhn; Grace M Aldrovandi; Moses Sinkala; Chipepo Kankasa; Mwiya Mwiya; Donald M Thea Journal: AIDS Date: 2010-06-01 Impact factor: 4.177
Authors: Jose H Pilotto; Luciane S Velasque; Ruth K Friedman; Ronaldo I Moreira; Valdilea G Veloso; Beatriz Grinsztejn; Mariza G Morgado; D Heather Watts; Judith S Currier; Risa M Hoffman Journal: Antivir Ther Date: 2011
Authors: Jean B Nachega; Vincent C Marconi; Gert U van Zyl; Edward M Gardner; Wolfgang Preiser; Steven Y Hong; Edward J Mills; Robert Gross Journal: Infect Disord Drug Targets Date: 2011-04
Authors: Bingxia Wang; Elena Losina; Ruth Stark; Alison Munro; Rochelle P Walensky; Marisa Wilke; Des Martin; Zhigang Lu; Kenneth A Freedberg; Robin Wood Journal: S Afr Med J Date: 2011-04
Authors: Alexandra Coria; Francine Noel; Jerry Bonhomme; Vanessa Rouzier; Christian Perodin; Adias Marcelin; Zhongze Li; Tor D Tosteson; Marie-Marcelle Deschamps; Peter F Wright; Jean W Pape Journal: J Acquir Immune Defic Syndr Date: 2012-12-15 Impact factor: 3.731
Authors: David Chilongozi; Lei Wang; Lillian Brown; Taha Taha; Megan Valentine; Lynda Emel; Moses Sinkala; George Kafulafula; Ramadhani A Noor; Jennifer S Read; Elizabeth R Brown; Robert L Goldenberg; Irving Hoffman Journal: Pediatr Infect Dis J Date: 2008-09 Impact factor: 2.129
Authors: Wafaie W Fawzi; Gernard I Msamanga; David Hunter; Boris Renjifo; Gretchen Antelman; Heejung Bang; Karim Manji; Saidi Kapiga; Davis Mwakagile; Max Essex; Donna Spiegelman Journal: AIDS Date: 2002-09-27 Impact factor: 4.177
Authors: Elizabeth R Brown; Phelgona Otieno; Dorothy A Mbori-Ngacha; Carey Farquhar; Elizabeth M Obimbo; Ruth Nduati; Julie Overbaugh; Grace C John-Stewart Journal: J Infect Dis Date: 2009-05-01 Impact factor: 5.226
Authors: Alison C Roxby; Jennifer A Unger; Jennifer A Slyker; John Kinuthia; Andrew Lewis; Grace John-Stewart; Judd L Walson Journal: Curr HIV/AIDS Rep Date: 2014-06 Impact factor: 5.071
Authors: Risa M Hoffman; Konstantia Nadia Angelidou; Sean S Brummel; Friday Saidi; Avy Violari; Dingase Dula; Vidya Mave; Lee Fairlie; Gerhard Theron; Moreen Kamateeka; Tsungai Chipato; Benjamin H Chi; Lynda Stranix-Chibanda; Teacler Nematadzira; Dhayendre Moodley; Debika Bhattacharya; Amita Gupta; Anne Coletti; James A McIntyre; Karin L Klingman; Nahida Chakhtoura; David E Shapiro; Mary Glenn Fowler; Judith S Currier Journal: HIV Clin Trials Date: 2018-12
Authors: Vivek Naranbhai; Dhayendre Moodley; Tsungai Chipato; Lynda Stranix-Chibanda; Clemensia Nakabaiito; Moreen Kamateeka; Philippa Musoke; Karim Manji; Kathleen George; Lynda M Emel; Paul Richardson; Philip Andrew; MaryGlenn Fowler; Helen Fletcher; Helen McShane; Hoosen M Coovadia; Adrian V S Hill Journal: J Acquir Immune Defic Syndr Date: 2014-12-15 Impact factor: 3.731
Authors: Sheree R Schwartz; Newton Kumwenda; Johnstone Kumwenda; Shu Chen; Lynne M Mofenson; Allan W Taylor; Mary Glenn Fowler; Taha E Taha Journal: Matern Child Health J Date: 2016-03